baber/WOPTO huggingface dataset:
Patent NZ-578143-A (NZ)
Title: A wind turbine apparatus
Inventor: ATTEY GRAEME SCOTT
IPC: F03D3/06
Filed: 2007-12-04
Abstract: 578143 Disclosed Is a horizontal axis wind turbine for generating electricity. The apparatus includes a plurality of elongated turbine blades rotatably mounted about an axis, each turbine blade extending generally parallel to the axis and having an aerofoil shaped profile. A pair of diametrically opposed wind deflection members are positioned at opposite ends of a diameter of the wind turbine apparatus such that, when the wind direction is perpendicular to said diameter, the turbine blades and deflection members are exposed to an open, unobstructed wind flow. Each turbine blade has a leading edge, a trailing edge and a thickest portion there between, and wherein a line segment drawn from the axis to the centre of a thickest portion of a turbine blade and a line segment drawn from the centre of the thickest portion of the turbine blade to the trailing edge of the turbine blade define an angle of less than 90 DEGREE .
Patent NZ-584494-A (NZ)
Title: Balustrade tubular connector insertable through aperture in rail of balustrade and having protrusion to abut inside of rail and act against removal from rail
Inventor: ARENA MICHAEL
IPC: E04F11/18
Filed: 2008-10-08
Abstract: A connector for connecting a wire to a balustrade rail, the connector comprising: a tubular body for receipt therein of a wire end portion (with the wire typically being crimped inside the tubular portion) and for positioning in the rail through a rail aperture; an opening in the tubular body for the wire to extend from the connector when the wire end portion is located in the tubular body; and a deflector (typically a lip of the tubular body) for deflecting the wire at an angle to the wire end portion which is held in the tubular body, when the wire is under tension. A protrusion from the tubular body abuts the inside of the balustrade rail and acts against the connector being removed from the rail when the wire is under tension and extending through the balustrade rail aperture.
Patent NZ-585110-A (NZ)
Title: Method and compositions for diagnosis and treatment of amyloidosis
Inventor: PFEIFER ANDREA
IPC: A61K39/395
Filed: 2008-10-03
Abstract: Disclosed is the use of a humanized antibody or an active fragment thereof, which recognizes and binds to beta-amyloid, comprising: (i) an HCVR comprising, integrated into human- or primate-derived framework regions: (a) a CDR1 comprising the amino acid sequence of SEQ ID NO: 1, (b) a CDR2 comprising the amino acid sequence of SEQ ID NO: 2, (c) a CDR3 comprising the amino acid sequence of SEQ ID NO: 3, (d) a serine in Kabat position 94, and (e) a leucine in Kabat position 47; and (ii) an LCVR comprising, integrated into human- or primate-derived framework regions: (a) a CDR1 comprising the amino acid sequence of SEQ ID NO: 4, (b) a CDR2 comprising the amino acid sequence of SEQ ID NO: 5 or the amino acid sequence of SEQ ID NO: 5 with one amino acid substitution, and (c) a CDR3 comprising the amino acid sequence of SEQ ID NO: 6, for the manufacture of a medicament for reducing the plaque load in the retinal ganglion cell layer of a subject suffering from cortical visual deficits, glaucoma, optic nerve drusen, optic neuropathy, optic neuritis, cataract, ocular amyloidosis or lattice dystrophy.
Patent NZ-585332-A (NZ)
Title: 4(-3-(-2-(phenyl)morpholino)-2-oxopyrrolidin-1-yl)-n-(thiazol-2-yl)benzenesulfonamide derivati ves and related compounds as modulators of ion channels for the treatment of pain
Inventor: STAMOS DEAN
IPC: A61K31/427
Filed: 2008-11-12
Abstract: The disclosure relates to heterocyclic derivatives of formula (I) and pharmaceutically acceptable salts thereof that are useful as inhibitors of ion channels, which makes them suitable for the treatment of various type of pain., (I) or a pharmaceutically acceptable salt thereof, wherein, independently for each occurrence: ring Z is a thiazole or thiadiazole optionally substituted with 0-2 occurrences of R; V is CH2, NH, O, or S; and R, R1, R2, and R3 are hydrogen, C1-C6 aliphatic, aryl, C3-C8 cycloaliphatic, halo, CN, NO2, CF3, OCF3, OH, NH2, NH(C1-C6 aliphatic), N(C1-C6 aliphatic)2, COOH, COO(C1 -C6 aliphatic), O(C1-C6 aliphatic), CHF2, or CH2F.
Patent NZ-589507-A (NZ)
Title: Light duty liquid cleaning compositions comprising surfactants, gellan gum and acids
Inventor: SZEWCZYK GREGORY
IPC: C11D3/20
Filed: 2008-06-17
Abstract: Disclosed is an acidic cleaning composition comprising: (i) a first anionic surfactant such as sodium dodecyl benzene sulfonate or paraffine sulfonate, (ii) a second anionic surfactant such as sodium lauryl ether sulphate with ethylene oxide units, (iii) at least one zwitterionic surfactant such as betaine, (iv) a suspending agent comprising gellan gum; and (v) one or more acids selected from the group consisting of citric acid, oxalic acid, sorbic acid, acetic acid, tartaric acid, formic acid, maleic acid, adipic acid, lactic acid, malic acid, malonic acid, glycolic acid, propanoic acid, propionic acid, and mixtures thereof,
Patent NZ-589810-A (NZ)
Title: A method for increasing bone density and/or reducing any osteochondral defects in an equne or avian and a composition including vitamin k
Inventor: BIFFIN JOHN RAY
IPC: A23L33/15
Filed: 2009-06-02
Abstract: Provided is a method of increasing bone density, maintaining bone density and/or inhibiting loss of bone density and/or reducing osteochondral defects in an equine comprising administering to an equine an effective amount of a UV stable composition containing: vitamin K1, vitamin K2 or a mixture of vitamin KI and vitamin K2, together with a UV absorber and a physiologically acceptable carrier, excipient and/or diluent. The composition may be encapsulated in cyclodextrin and contain beta-carotene.
Patent NZ-594460-A (NZ)
Title: Removable nozzle
Inventor: VAN ERDEN DONALD L
IPC: B05C17/005
Filed: 2010-01-15
Abstract: 594460 A nozzle (148) for dispensing sealant. The nozzle includes a nozzle head (150) having a body section forming a primary channel through which sealant is dispensed, the primary channel forming an entrance through which sealant enters the body section and an exit through which sealant is dispensed from the nozzle; and a base portion (180) connected with the nozzle head and having a coupling member for fastening the base portion to a sealant container. The coupling member has a first fastener configured to mate with a second fastener of the sealant container. The base portion has a piercing member used to pierce a top surface of the sealant container. The second fastener forms an opening. The piercing member is configured to be inserted into the opening.
Patent NZ-594687-A (NZ)
Title: Electrical plug
Inventor: CHOI MIN-KYU
IPC: H01R13/68
Filed: 2010-02-04
Abstract: 594687 Disclosed is an electrical plug which is collapsible to occupy less space. The electrical plug comprises a plug main body (3), a plurality of electrical pins (15, 21, 23) carried by a pivotal arm (17) coupled to the plug main body, and first and second wings (5, 7) hingedly carried by the plug main body. The pivotal arm is rotatable relative to the main body between a stowed position, whereby the arm is generally linearly aligned with the main body, and a deployed position, whereby the arm is generally perpendicular to the main body. The first and second wings can be moved relative to the main body from a stowed position, whereby the wings at least partially cover the electrical pins of the pivotal arm in the stowed position, and a deployed position, whereby the wings are opened to expose the electrical pins. In use, the plug may be engaged with a socket when in the deployed position, whereby the wings at least partially obstruct access to the electrical pins. A multiplug adaptor, including one or more of the aforementioned electrical plugs, is also disclosed.
Patent NZ-594952-A (NZ)
Title: Oral dosage forms having a high loading of a gabapentin prodrug
Inventor: KARABORNI SAMI
IPC: A61K9/16
Filed: 2010-03-05
Abstract: 594952 Disclosed herein is a tablet dosage form comprising 85 wt-% to 95 wt-% 1-([(?-isobutanoyl-oxyethoxy)carbonyl]aminomethyl)-1-cyclohexane acetic acid (1) or a pharmaceutically acceptable salt thereof, wherein the tablet is prepared by compressing granules comprising greater than 95 wt-% 1-([(?-isobutanoyloxyethoxy)carbonyl]aminomethyl)-1-cyclohexane acetic acid or a pharmaceutically acceptable salt thereof, and the use of said tablet in the treatment of epilepsy, essential tremor, chronic regional pain syndrome, fibromyalgia, radiculopathy, abdominal-visceral pain, irritable bowel syndrome, migraine, generalized anxiety disorder, depression, insomnia, overactive bladder, hot flashes, premature ejaculation, restless legs syndrome, neuropathic pain, chronic lower back pain, alcohol dependency, complex regional pain syndrome, post-operative pain, cancer-induced pain, bipolar disorder, social anxiety disorder, Parkinson's disease, asthma, cough, chronic obstructive pulmonary disease, and vulvodynia. In one embodiment the tablet further comprises 3 wt-% to 15 wt-% hydroxypropylmethyl cellulose, and 2 wt-% to 3 wt-% lubricant, wherein the lubricant is selected from calcium stearate, glyceryl behenate, glyceryl monostearate, magnesium stearate, mineral oil, polyethylene glycol, sodium stearyl fumarate, sodium lauryl sulfate, sodium dodecyl sulfate, stearic acid, talc, hydrogenated vegetable oil, zinc stearate, and combinations of any of the foregoing.
Patent NZ-599423-A (NZ)
Title: Improvements in incontinence monitoring and assessment
Inventor: CURRAN PETER
IPC: A61F13/15
Filed: 2010-11-05
Abstract: Disclosed is a system (100) for monitoring incontinence in one or more subjects (106). The system (100) includes a display means (103), input means (104) operable by a user, one or more transmitters (R1, R2), each transmitter being associated with one or more subjects being monitored (106) and configured to transmit signals containing continence-related data for the one or more subjects (106). The continence-related data has been obtained over time from a continence sensor associated with an absorbent article worn by each respective subject (106). A receiver unit (112) receives signals from the one or more transmitters (R1, R2) and a processing means (102) is in communication with at least the receiver unit (112). The processing means (102) includes a display processor configured to process the received signals and communicate display information to the display means (103) for display of a visual representation of continence-related information derived from continence sensors in the absorbent articles worn by the one or more subjects (106) being monitored. The processing means (102) receives automatically, a sensor status indicator which indicates whether a sensor, or absorbent article associated with a sensor, is newly connected to the system or re-connected to the system (100).
Patent NZ-600674-A (NZ)
Title: Quinoline amide m1 receptor positive allosteric modulators
Inventor: KUDUK SCOTT D
IPC: A01N43/42
Filed: 2010-12-13
Abstract: 600674 Disclosed herein is a quinoline-2-carboxamide compounds of formula (I), wherein the variables are defined in the specification, and the use thereof in the treatmet of a disease mediated by the muscarinic M1 receptor, wherein said disease is selected from the group consisting of Alzheimer's disease, schizophrenia, pain or sleep disorders. Specific embodiments of the quinoline-2-carboxamide compound include: 4-[(6-chloropyridin-3-yl)methyl]-N-[(1S,2S)-2-hydroxycyclohexyl]quinoline-2-carboxamide, N-[(3S,4S)-4-hydroxytetrahydro-2H-pyran-3-yl]-4-{ [6-(1-methyl-1H-pyrazol-4-yl)pyridin-3-yl]methyl} quinoline-2-carboxamide, 4-[fluoro(6-methoxypyridin-3-yl)methyl]-N-[(3R,4S)-3-hydroxytetrahydro-2H-pyran-4-yl]quinoline-2-carboxamide hydrate, 4-[(2-ethoxypyridin-4-yl)methyl]-N-[(3R,4S)-3-hydroxytetrahydro-2H-pyran-4-yl]quinoline-2-carboxamide.
Patent NZ-603191-A (NZ)
Title: Methods for the treatment of il-1b related conditions
Inventor: GUL AHMET
IPC: C07K16/24
Filed: 2011-05-06
Abstract: Disclosed is the use of an anti-IL-1β antibody or antigen binding fragment thereof in the manufacture of a medicament for the treatment of treatment refractory uveitis in a subject, wherein the antibody or antigen binding fragment thereof binds to human IL-1β.
Patent NZ-610368-A (NZ)
Title: Specially designed magnesium-aluminum alloys and medical uses thereof in a hemodynamic environment
Inventor: GREEN STEPHEN
IPC: C22C23/02
Filed: 2011-11-09
Abstract: A closure device implant for sealing an opening formed through a blood vessel, said closure device comprising a footplate portion at least partially exposed to the lumen of the blood vessel when in use. The footplate portion is formed of a biocorrodible metal comprising a magnesium alloy formulated with a corrosion activator comprising between 0.01% and 0.08% iron, wherein said footplate portion’s magnesium alloy comprises between about 1% to 8.25% aluminium. The magnesium alloy formulated with the corrosion activator is formulated to have a faster corrosion rate in a hemodynamic environment than a corrosion rate of AZ31.
Patent NZ-613474-A (NZ)
Title: An ac or dc power transmission system and a method of measuring a voltage
Inventor: JESPERSEN PER
IPC: G01R15/24
Filed: 2012-01-17
Abstract: The present invention relates to an AC or DC power transmission system. The system comprises a first electrical conductor, a second electrical conductor and an insulating space there between. The system further comprises an electric field measurement device comprising the following components being mounted in optical continuation: a first optical fibre being connected to a light source, a first optical lens, a circular polarization filter, a crystal rod having electro-optical properties, a linear polarization filter, a second optical lens, and a second optical fibre being connected to a light detection unit. The electric field measurement device is located adjacent the first electrical conductor and defines a first minimum distance between the crystal rod and the first electrical conductor and a second minimum distance between the crystal rod and the second electrical conductor. The second minimum distance is at least 10 times larger than the first minimum distance.
Patent NZ-616550-A (NZ)
Title: Treatment of microbial infections using reactive oxygen species
Inventor: O’FLAHERTY VINCENT
IPC: A61P31/02
Filed: 2012-04-16
Abstract: Provided are microbiocidal compositions comprising reactive oxygen species (ROS) or comprising components that produce ROS. The components that produce ROS may be an enzyme such as lactoperoxidase, chloroperoxidase, bromoperoxidase or iodooxidase and its corresponding substrate. For example a composition may comprise potassium iodide, lactoperoxidase and glucose oxidase. The compositions may be used in in the treatment of microbial infections or in the control of microbial contamination. The compositions may be particularly useful in the treatment of mastitis.
Patent NZ-623574-A (NZ)
Title: Ketolide compounds
Inventor: TRIVEDI BHARAT
IPC: C07H17/08
Filed: 2011-02-03
Abstract: 623574 Disclosed are ketolide compounds of Formula (I) and their pharmaceutically acceptable salts, solvates, hydrates, polymorphs and stereoisomers having antimicrobial activity. Also disclosed are pharmaceutical compositions containing the compounds of formula (I) and methods of treating or preventing microbial infections with the compounds of formula (I), wherein, T is -C*H(R1)-P-Q; R1 is unsubstituted or substituted lower alkyl, cycloalkyl or aryl; P is heteroaryl ring; Q is unsubstituted or substituted aryl or heteroaryl ring; and P is attached to Q via carbon-carbon link; and R3 is Hydrogen or fluorine. Examples of compounds of formula (I) are: (11S,21R)-3-decladinosyl-11,12-dideoxy-6-O-methyl-3-oxo-12,11-{ oxycarbonyl-[E-N-[1-(5-pyridin-2-yl-1,3,4-thiadiazol-2-yl)-(S)-ethoxy]-carboxamidino]methylene} -erythromycin A and (11S,21R)-3-decladinosyl-11,12-dideoxy-6-O-methyl-3-oxo-12,11-{ oxycarbonyl-[E-N-[1-(5-pyrimidin-2-yl-1,3,4-thiadiazol-2-yl)-(S)-ethoxy]-carboxamidino]methylene} -erythromycin A.
Patent NZ-631452-A (NZ)
Title: Nutritionally balanced food or beverage product
Inventor: POPE-MAYELL GUY WILLIAM CLAYTON
IPC: A23L2/38
Filed: 2012-03-13
Abstract: Disclosed is a process for manufacturing a food or beverage product which is based upon the nutritional reference values (NRV) as a starting point and which has a focus on increasing or decreasing the relative amounts of one macronutrient yet is balanced with respect to the other macronutrients, the process comprising the steps of: (i) selecting a first non-zero percentage of the (NRV) that will be used to determine an amount of two macronutrients selected from protein, fat or carbohydrate that will be in the product , from any one of the following documents: Daily Reference Values given in USFDA Code of Federal Regulations 21 CFR 101.9, 1996; - % Daily Intake reference values given in the Australia New Zealand Food Standards; - GDA –Guideline Daily Amounts as published by the Food and Drink Federation, UK; - Reference Standards given in The Canadian Food and Drug Regulations and amendments; all as published on 13 March 2012; (ii) selecting a second percentage of the NRV that will be used to determine an amount of the third macronutrient that will be in the product, wherein said second percentage of the NRV for the third macronutrient, not selected in step (i), is not the same as the first percentage for the other two macronutrients; and (iii) combining the protein, fat and carbohydrate macronutrients in amounts as determined at steps (i) and (ii) above; and (iv) optionally adding fibre in the same relative proportions of the NRV as the two selected macronutrients, wherein the same relative proportion of the NRV is substantially within 5% to 50% of the daily intake for each of selected macronutrients.
Patent NZ-702126-A (NZ)
Title: Shipping container ventilation apparatus
Inventor: NICHOLAS MARK SELF
IPC: A01M17/00
Filed: 2013-11-26
Abstract: The invention relates to a shipping container ventilation apparatus which includes a collection nozzle arranged to project into the interior of a shipping container. The apparatus also includes a transport duct connected to the collection nozzle, the transport duct having a length at least equal to the thickness of a shipping container door and being arranged to extend from the exterior of a shipping container to the interior of the shipping container when located between two closed container doors. A pressure equalisation chamber is also provided which is connected to the transport duct distal to the collection nozzle, the pressure equalisation chamber having a height at least equal to the height of the transport duct. The invention also includes at least one gas line coupling associated with the pressure equalisation chamber, and is arranged so that the width of the collection nozzle is at least greater than the width of the transport duct. In preferred forms the invention can provide a portable apparatus used in the fumigation and/or subsequent ventilation of a shipping container which can be used by one person to quickly ventilate a container.
Patent NZ-702849-A (NZ)
Title: Genotype- or phenotype-based drug formulation
Inventor: WILLMANN STEFAN
IPC: A61P35/00
Filed: 2013-05-27
Abstract: The invention relates to a combination of two or more pharmaceutically active substances, which comprises a parent substance and at least one metabolite thereof. In particular, the present invention relates to a fixed-dose combination pharmaceutical formulation comprising tamoxifen and at least one metabolite thereof.
Patent NZ-710666-A (NZ)
Title: Tricycle
Inventor: NEERMAN JOHAN
IPC: B62K15/00
Filed: 2014-03-10
Abstract: This invention relates to a folding tricycle (1) for transporting a person. In order to overcome problems associated with the storage of tricycles generally, it is possible to reduce the dimensions of the width and length of the tricycle (1), and without compromising the ability of the tricycle (1) to drive/ride. To achieve this, the folding tricycle (1) comprises a front wheel (2), two rear wheels (3) and a frame joining the wheels (2, 3) wherein the frame comprises two arms (7) that carry the rear wheels (3). The arms (7) are connected to the rest of the frame in such a manner that the arm (7) can adopt different positions relative to the rest of the frame. The dimensions of the width and length of the tricycle (1) are therefore adjustable, for storage purposes, as aforesaid, and the ability of the tricycle (1) to be driven/ridden is not compromised.
Patent NZ-711191-A (NZ)
Title: Benzo-fused heterocyclic derivatives useful as agonists of gpr120
Inventor: SUI ZHIHUA
IPC: C07D263/56
Filed: 2014-03-07
Abstract: The present invention is directed to benzo-fused heterocyclic derivatives of formula (I), pharmaceutical compositions containing them and their use in the treatment of disorders and conditions modulated by GPR120. More particularly, the compounds of the present invention are agonists of GPR120, useful in the treatment of, such as for example, Type II diabetes mellitus.
Patent NZ-711946-A (NZ)
Title: Newcastle disease viruses and uses thereof
Inventor: GARCIA-SASTRE ADOLFO
IPC: C12N15/09
Filed: 2014-03-04
Abstract: The present invention relates to the combination therapy of NDV and anti-PD-1 antibodies for the treatment of cancer. Further described herein are chimeric Newcastle disease viruses engineered to express an agonist of a co-stimulatory signal of an immune cell and compositions comprising such viruses. Also described herein are chimeric Newcastle disease viruses engineered to express an antagonist of an inhibitory signal of an immune cell and compositions comprising such viruses. The chimeric Newcastle disease viruses and compositions are useful in the treatment of cancer. In addition, described herein are methods for treating cancer comprising administering Newcastle disease viruses in combination with an agonist of a co-stimulatory signal of an immune and/or an antagonist of an inhibitory signal of an immune cell.
Patent NZ-721405-A (NZ)
Title: Process for extracting lipids for use in production of biofuels
Inventor: APT KIRK
IPC: C11B1/12
Filed: 2014-12-18
Abstract: Methods and systems used to extract lipids suitable in production of biofuels from a fermentation broth may include using heat to pre-treat the fermentation broth in order to more easily extract a product from oleaginous microorganisms in the broth. Additionally or alternatively, a combination of enzymes including amylase, 1-4 mannosidase, and 1-3 mannosidase may be used to break down cell walls of the oleaginous microorganisms. Residual broth water may be recycled and used as imbibition water for washing a process feedstock to extract sugar.
Patent NZ-734532-A (NZ)
Title: Genetically modified major histocompatibility complex mice
Inventor: MACDONALD LYNN
IPC: A01K67/027
Filed: 2012-10-26
Abstract: Disclosed is a non-human animal comprising at an endogenous non-human β2 microglobulin locus a nucleic acid sequence comprising exons 2, 3, and 4 of a human β2 microglobulin gene, wherein the nucleic acid sequence encodes a polypeptide comprising a human β2 microglobulin amino acid sequence, and wherein the non-human animal expresses the human or humanized β2 microglobulin polypeptide.